Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment

Molecular Medicine Reports

Volumn 6, Issue 6, 2012, Pages 1450-1454

  Li, Qiang ^a   Chen, Min ^a   Liu, Hongmin ^a   Yang, Liqun ^a   Yang, Guiying ^a  

^a QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

amyloid protein; Alzheimer's disease; Donepezil hydrochloride; Free radical; Morris water maze

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; CATALASE; CHOLINE ACETYLTRANSFERASE; DONEPEZIL; GLUTATHIONE PEROXIDASE; MESSENGER RNA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LEARNING; MALE; MAZE TEST; MEMORY; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CATALASE; CHOLINE O-ACETYLTRANSFERASE; DISEASE MODELS, ANIMAL; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; INDANS; LEARNING; MALE; MEMORY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84868568082     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1102     Document Type: Article

References (29)

1. Lee DY, Fletcher E, Martinez O, et al: Vascular and degenerative processes differentially affect regional interhemispheric connections in normal aging, mild cognitive impairment, and Alzheimer disease. Stroke 41: 1791-1797, 2010.
2. Aluise CD, Robinson RA, Beckett TL, et al: Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39: 221-228, 2010.
3. Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC and Tan EK: The roles of amyloid precursor protein (APP) in neurogenesis: implications to pathogenesis and therapy of Alzheimer disease. Cell Adh Migr 5: 280-292, 2011.
4. Armstrong J, Boada M, Rey MJ, Vidal N and Ferrer I: Familial Alzheimer disease associated with A713T mutation in APP Neurosci Lett 370: 241-243, 2004
5. Esh C, Patton L, Kalback W, et al: Altered APP processing in PDAPP (Val717→Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry 44: 13807-13819, 2005.
6. Ceballos-Picot I, Nicole A and Sinet PM: Cellular clones and transgenic mice overexpressing copper-zinc superoxide dismutase: models for the study of free radical metabolism and aging EXS 62: 89-98, 1992.
7. Moon EY, Oh JM, Kim YH, Ryoo IJ and Yoo ID: Clitocybins, novel isoindolinone free radical scavengers, from mushroom Clitocybe aurantiaca inhibit apoptotic cell death and cellular senescence. Biol Pharm Bull 32: 1689-1694, 2009.
8. Percy ME, Dalton AJ, Markovic VD, et al: Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease. Am J Med Genet 35: 459-467 1990.
9. Loewenstein DA, Acevedo A, Czaja SJ and Duara R: Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry 12: 395-402, 2004.
10. Lamirault L, Guillou C, Thal C and Simon R: (-)-9-Dehydro-galanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats. Neurobiol Learn Mem 80: 113-122, 2003.
11. Gibb WR, Mountjoy CQ, Mann DM and Lees AJ: Pathological study of the association between Lewy body disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry 52: 701-708, 1989.
12. Tohgi H, Abe T, Rashiguchi K, Saheki M and Takahashi S: Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett 177: 139-142, 1994.
13. Li J, Wang G, Liu J, et al: Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo. Eur J Pharmacol 649: 195-201, 2010.
14. Kim JW, Lee DY, Choo IH, et al: Microstructural alteration of the anterior cingulum is associated with apathy in Alzheimer disease. Am J Geriatr Psychiatry 19: 644-653, 2011.
15. Saber AJ and Cain DP: Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. Neuropsychopharmacology 28: 1247-1256, 2003.
16. Wang L, Khan A, Csernansky JG, et al: Fully-automated, multi-stage hippocampus mapping in very mild Alzheimer disease. Hippocampus 19: 541-548, 2009.
17. Polidori MC and Mecocci P: Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 4: 517-522, 2002.
18. Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA and Perry G: Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol 610: 419-434, 2010:
19. Aksenov MY, Tucker HM, Nair P, et al: The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Mol Neurosci 11: 151-164, 1998.
20. Evereklioglu C, Er H, Doganay S, et al: Nitric oxide and lipid peroxidation are increased and associated with decreased antioxidant enzyme activities in patients with age-related macular degeneration. Doc Ophthalmol 106: 129-136, 2003.
21. Bales KR, Tzavara ET, Wu S, et al: Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody J Clin Invest 116: 825-832, 2006.
22. Xiao F, Li XG, Zhang XY, et al: Combined administration of D-galactose and aluminium induces Alzheimer-like lesions in brain. Neurosci Bull 27: 143-155, 2011.
23. Lestaevel P, Bensoussan H, Racine R, Airault F, Gourmelon P and Souidi M: Transcriptomic effects of depleted uranium on acetylcholine and cholesterol metabolisms in Alzheimer's disease model. C R Biol 334: 85-90, 2011.
24. Sultana R, Robinson RA, Di Domenico F, et al: Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J Proteomics 74: 2430-2440, 2011.
25. Monji A, Utsumi H, Ueda T, et al: Amyloid-beta-protein (A beta) (25-35)-associated free radical generation is strongly influenced by the aggregational state of the peptides. Life Sci 70: 833-841, 2002.
26. Tamaoka A, Fraser PE, Ishii K, et al: Amyloid-beta-protein isoforms in brain of subjects with PS1-linked, beta APP-linked and sporadic Alzheimer disease. Brain Res Mol Brain Res 56: 178-185, 1998.
27. Jeong SJ, Kim K and Suh YH: Age-related changes in the expression of Alzheimer's beta APP in the brain of senescence accelerated mouse (SAM)-P/10. Neuroreport 8: 1733-1737, 1997.
28. Mishra S and Caflisch A: Dynamics in the active site of β-secretase: a network analysis of atomistic simulations. Biochemistry 50: 9328-9339, 2011.
29. Singer O, Marr RA, Rockenstein E, et al: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343-1349, 2005.